Department of Orthopedics, Peking University First Hospital, No. 8 Xishiku Street, XiCheng District, Beijing, 100034, People's Republic of China.
J Orthop Surg Res. 2020 Dec 1;15(1):577. doi: 10.1186/s13018-020-02105-7.
Dexmedetomidine has shown potential in pain control in patients undergoing total knee arthroplasty (TKA). However, the combination of nerve block and dexmedetomidine may be a preferred alternative for postoperative analgesia after TKA. The aim of this study was to perform a meta-analysis on existing randomized controlled trials (RCTs) to determine the efficacy and safety of dexmedetomidine as an adjunct to local anesthetics in nerve block after TKA.
A literature survey was conducted in the databases of PubMed, Embase, Cochrane Library, Web of science, and ScienceDirect for the RCTs completed before February 1st, 2020 that met pre-specified inclusion criteria. The primary outcomes included the pain scores, duration of analgesia, opioid consumption within 24 h postoperatively, and the level of patient satisfaction. The secondary outcomes included the motor strength, degree of sedation, postoperative nausea and vomiting, and other related complications. The methodological quality was assessed by the Cochrane risk of bias tool.
The initial literature search yielded 143 studies, out of which seven studies met the inclusion criteria. The pooled data indicated that dexmedetomidine combined with local anesthetics in nerve block in TKA decreased the postoperative pain scores at rest as well as at motion (SMD = - 1.01 [95% CI - 1.29 to - 0.72], p < 0.01; SMD = - 1.01 [- 1.25 to - 0.77], p < 0.01) respectively, decreased the total opioid consumption within 24 h (SMD = - 0.63 [- 0.86 to - 0.40], p < 0.01), prolonged the duration of analgesia (SMD = 0.90 [0.64 to 1.17], p < 0.01), improved motor strength (SMD = 0.23 [0.01 to 0.45], p = 0.04), improved the degree of sedation (SMD = 0.94 [0.70 to 1.18], p < 0.01), and increased the level of patient satisfaction (SMD = 0.88 [0.60 to 1.17], p < 0.01) without increasing nausea and vomiting (RD = - 0.05 [- 0.11 to 0.01], p = 0.14), as well as other complications (RD = - 0.01 [- 0.08 to 0.07], p = 0.89), compared with local anesthetics alone.
It is effective and safe for dexmedetomidine as an adjunct to local anesthetics in nerve block in TKA to relieve postoperative pain, decrease total opioid consumption, prolong analgesic duration, and increase patient satisfaction without increasing related complications. Based on the quality of evidence, this meta-analysis recommends that dexmedetomidine can be used in a regular treatment regimen and as an adjunct addition to local anesthetics in nerve block for patients undergoing TKA.
This meta-analysis was prospectively registered on PROSPERO (International prospective register of systematic reviews) and the registering number was CRD42020169171.
右美托咪定在全膝关节置换术(TKA)患者的疼痛控制中显示出了潜力。然而,神经阻滞联合右美托咪定可能是 TKA 后术后镇痛的首选替代方案。本研究的目的是对现有的随机对照试验(RCT)进行荟萃分析,以确定右美托咪定作为局部麻醉剂在 TKA 后神经阻滞中的辅助用药的疗效和安全性。
在 2020 年 2 月 1 日之前完成的文献中,我们在 PubMed、Embase、Cochrane 图书馆、Web of science 和 ScienceDirect 数据库中进行了文献检索,以确定符合预设纳入标准的 RCT。主要结局包括疼痛评分、镇痛持续时间、术后 24 小时内阿片类药物的消耗量以及患者满意度。次要结局包括运动力量、镇静程度、术后恶心和呕吐以及其他相关并发症。采用 Cochrane 偏倚风险工具评估方法学质量。
最初的文献检索产生了 143 项研究,其中 7 项研究符合纳入标准。汇总数据表明,右美托咪定联合局部麻醉剂在 TKA 中的神经阻滞中降低了术后静息和运动时的疼痛评分(SMD = -1.01 [95% CI -1.29 至 -0.72],p < 0.01;SMD = -1.01 [-1.25 至 -0.77],p < 0.01),降低了术后 24 小时内阿片类药物的总消耗量(SMD = -0.63 [-0.86 至 -0.40],p < 0.01),延长了镇痛持续时间(SMD = 0.90 [0.64 至 1.17],p < 0.01),改善了运动力量(SMD = 0.23 [0.01 至 0.45],p = 0.04),改善了镇静程度(SMD = 0.94 [0.70 至 1.18],p < 0.01),并提高了患者满意度(SMD = 0.88 [0.60 至 1.17],p < 0.01),而不会增加恶心和呕吐(RD = -0.05 [-0.11 至 0.01],p = 0.14)或其他并发症(RD = -0.01 [-0.08 至 0.07],p = 0.89)与单独使用局部麻醉剂相比。
在 TKA 中,右美托咪定联合局部麻醉剂进行神经阻滞可以有效且安全地缓解术后疼痛,减少阿片类药物的总消耗量,延长镇痛持续时间,并提高患者满意度,而不会增加相关并发症。基于证据质量,本荟萃分析建议将右美托咪定纳入常规治疗方案,并作为 TKA 患者神经阻滞中局部麻醉剂的辅助用药。
本荟萃分析在 PROSPERO(国际系统评价注册库)中进行了前瞻性注册,注册编号为 CRD42020169171。